A Phase 1b, Multicenter, Open Label Study to Evaluate the Safety, Pharmacokinetics and Efficacy of AT 1501 in Patients Undergoing Kidney Transplant
Latest Information Update: 07 Jun 2024
At a glance
- Drugs Tegoprubart (Primary) ; Antithymocyte globulin; Mycophenolate mofetil; Steroids
- Indications Renal transplant rejection
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Eledon Pharmaceuticals
- 03 Jun 2024 According to an Eledon Pharmaceuticals media release, data from this trial presented at the American Transplant Congress (ATC)
- 03 Jun 2024 Results published in the Eledon Pharmaceuticals Media Release
- 09 May 2024 According to an Eledon Pharmaceuticals media release, the company announced that it will participate in the American Transplant Congress (ATC) taking place in Philadelphia, PA from June 1-5, 2024. The Company will present a poster that features updated data from Eledon's ongoing open-label Phase 1b trial and open-label extension study. Poster Number: 6647